Search Results

Neuronascent Inc., a privately-held neuron regeneration therapeutics company, announced that the National Institute of Aging, has awarded a U01 grant to Neuronascent, with the CEO, Dr. Judith Kelleher-Andersson being the principal investigator.

Neuronascent Inc., a clinical-stage, neuron generating, biopharmaceutical company, is pleased to announce the addition of industry leader Emer Leahy, Ph.D., MBA, to its Board of Directors.

Neuronascent Inc., announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted for a poster presentation at the Alzheimer’s Association International Conference to be held in Amsterdam, Holland, on July 19, 2023.

Neuronascent Inc. announced that the US Food and Drug Administration granted rare pediatric designation for NNI-351 for Fragile X syndrome.

Neuronascent Inc, announced that the U.S. Food and Drug Administration granted “Orphan Drug Designation” for the company’s NNI-351 treatment of Fragile X Syndrome.

Neuronascent Inc., is a clinical-stage pharmaceutical company discovering and developing novel regenerative therapies for age-related brain disorders.

Neuronascent Inc., today announced its abstract entitled “Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures” has been accepted for a poster presentation at 15th Clinical Trials on Alzheimer’s Disease (CTAD 2022) to be held in San Francisco, Calif., on Nov. 29 through Dec. 2, 2022.

Neuronascent Inc., a clinical-stage pharmaceutical company developing first-in-class neuron generating therapeutics, today announced the completion of its Phase 1a trial of NNI-362 for Alzheimer’s disease.